Because scopolamine effectively models early AD-like cognitive deficits and neuroinflammatory responses, it is widely used to evaluate potential AD therapies, including cholinesterase inhibitors, anti-inflammatory agents, antioxidants, and neuroprotective compounds. Here, BCHE is linked to Alzheimer disease.